UBS Confirms Buy Recommendation for Sanofi
The Swiss bank UBS has rated Sanofi as “Buy” and set a price target of 115 Euros. This assessment is based on promising study data that is particularly significant for investors.
Focus on Study Data
Matthew Weston, an analyst at UBS, emphasizes the importance of the new study data from a competing drug to Sanofi’s Ayvakit, which is currently the only approved medication for the treatment of mastocytosis. The data shows comparable efficacy of the new drug Bezuclastinib, developed by Blueprint Medicines, a company acquired in June.
Price Target and Justification
- Classification: Buy
- Price Target: 115 Euros
- Reason: Positive study data for the treatment of mastocytosis
- Importance: Comparable efficacy of Bezuclastinib versus Ayvakit
- Source of Data: Blueprint Medicines
These developments in drug research strengthen confidence in Sanofi’s market position and justify the buy recommendation according to UBS.